Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
Key Highlights
- ➤Sanofi discontinued Phase 1 SAR448272 and terminated the STAT6 degrader program
- ➤Nurix loses future SAR448272 milestones and royalties under the Sanofi collaboration
- ➤Nurix held $1.1 billion in cash, equivalents and marketable securities as of August 31, 2026
- ➤Cash runway guidance remains unchanged, funding operations into the second half of 2029
- ➤Bexobrutideg advances in Phase 3 with Roche; NX-1607 and GS-6791/NX-0479 remain in Phase 1 trials
Expert Statements
Arthur T. Sands, M.D., Ph.D., President and chief executive officer of Nurix Therapeutics
“While today’s news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline.”
Arthur T. Sands, M.D., Ph.D., President and chief executive officer of Nurix Therapeutics
“Bexobrutideg, our lead BTK degrader program partnered with Roche, is advancing in a Phase 3 trial in patients with chronic lymphocytic leukemia; our wholly owned CBL-B inhibitor NX-1607 is advancing in multiple Phase 1b cohorts for patients with lung cancer, colon cancer, prostate cancer, and melanoma; and our IRAK4 degrader for rheumatoid arthritis, GS-6791/NX-0479 is advancing through Phase 1 trials with our partner Gilead.”
BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.
As a result of Sanofi’s decision, Nurix does not anticipate receiving any of the future development, regulatory and commercial milestone payments or royalties for which it has been eligible under the collaboration with respect to the SAR448272 program. Nurix remains eligible to receive milestone payments and royalties with respect to its other previously announced licensed programs developed under the collaboration agreement that Sanofi may at its discretion develop further into clinical candidates. Today’s announcement does not change Nurix’s recently issued cash runway guidance, with cash, cash equivalents and marketable securities of $1.1 billion as of August 31, 2026, sufficient to fund operations into the second half of 2029.
Get started
Create a free account to read the full story.